SeaCrest Wealth Management LLC Purchases New Holdings in Sanofi $SNY

Key Points

• SeaCrest Wealth Management LLC has purchased a new stake in Sanofi, acquiring 9,372 shares valued at approximately $453,000 in the second quarter.
• Sanofi's recent quarterly earnings showed an EPS of $0.90, missing estimates, while revenue was $11.34 billion, exceeding expectations.
• Several analysts have recently upgraded Sanofi's stock rating, raising it from "hold" to "buy" or "overweight," reflecting increased confidence in the company's potential.

SeaCrest Wealth Management LLC bought a new stake in Sanofi (NASDAQ:SNY - Free Report) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor bought 9,372 shares of the company's stock, valued at approximately $453,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. HF Advisory Group LLC raised its holdings in Sanofi by 1.4% in the 2nd quarter. HF Advisory Group LLC now owns 26,949 shares of the company's stock valued at $1,302,000 after acquiring an additional 377 shares during the period. Wealth Enhancement Advisory Services LLC grew its position in shares of Sanofi by 24.0% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 72,420 shares of the company's stock worth $3,498,000 after purchasing an additional 14,040 shares in the last quarter. Sivia Capital Partners LLC grew its position in shares of Sanofi by 5.4% during the 2nd quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company's stock worth $326,000 after purchasing an additional 347 shares in the last quarter. Dynamic Advisor Solutions LLC boosted its position in shares of Sanofi by 4.5% during the 2nd quarter. Dynamic Advisor Solutions LLC now owns 58,352 shares of the company's stock worth $2,819,000 after acquiring an additional 2,515 shares in the last quarter. Finally, Bruce G. Allen Investments LLC boosted its position in shares of Sanofi by 4.9% during the 2nd quarter. Bruce G. Allen Investments LLC now owns 5,476 shares of the company's stock worth $265,000 after acquiring an additional 257 shares in the last quarter. 14.04% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts recently commented on SNY shares. Wall Street Zen raised shares of Sanofi from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "hold" rating to a "buy" rating in a research note on Tuesday, September 2nd. Morgan Stanley raised shares of Sanofi from an "equal weight" rating to an "overweight" rating and raised their price target for the company from $56.00 to $58.00 in a research note on Monday, September 8th. Barclays reissued an "overweight" rating on shares of Sanofi in a research note on Wednesday, July 2nd. Finally, Guggenheim restated a "buy" rating on shares of Sanofi in a report on Tuesday, June 3rd. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $62.67.

Sanofi Stock Down 1.3%

Shares of SNY stock traded down $0.63 during trading hours on Monday, reaching $47.01. The company had a trading volume of 2,619,886 shares, compared to its average volume of 2,863,289. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27. The stock's fifty day simple moving average is $48.46 and its 200 day simple moving average is $50.67. Sanofi has a twelve month low of $44.73 and a twelve month high of $60.12. The company has a market capitalization of $115.43 billion, a P/E ratio of 11.30, a price-to-earnings-growth ratio of 1.12 and a beta of 0.51.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.96 by ($0.06). Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The company had revenue of $11.34 billion during the quarter, compared to the consensus estimate of $9.91 billion. During the same period last year, the business posted $1.73 EPS. The company's revenue for the quarter was down 7.0% on a year-over-year basis. As a group, sell-side analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.